The DOI matches its Crossref record; 119 of the 119 references it cites were found in a registry or an index.
Alpha‐Synuclein as a Biomarker for Parkinson's Disease
Open accessAbstract
Parkinson's disease (PD) is a common neurodegenerative disorder, characterized pathologically by the presence of α‐synuclein (α‐syn)‐rich Lewy bodies. As clinical diagnosis of PD is challenging, misdiagnosis is common, highlighting the need for disease‐specific and early stage biomarkers. Both early diagnosis of PD and adequate tracking of disease progression could significantly improve outcomes for patients, particularly in regard to existing and future disease modifying treatments. Given its critical roles in PD pathogenesis, α‐syn may be useful as a biomarker of PD. The aim of this review is, therefore, to summarize the efficacy of tissue and body fluid α‐syn measurements in the detection of PD as well as monitoring disease progression. In comparison to solid tissue specimens and biopsies, biofluid α‐syn levels may be the most promising candidates in PD diagnosis and progression based on specificity, sensitivity and availability. Although α‐syn has been tested most extensively in cerebrospinal fluid (CSF), the relatively invasive procedure for collecting CSF is not suitable in most clinical settings, leading to investigation of plasma, blood and saliva as alternatives. The exploration of combined biomarkers, along with α‐syn, to improve diagnostic accuracy is also likely required.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Although elevated concentrations of α-syn in blood have been proposed as an early biomarker of Parkinson’s disease, identifying brain-derived α-syn is challenging due to its ubiquitous presence in different tissues, such as CSF, blood, saliva, tears, and peripheral tissues [145, 146].”
From Extracellular vesicles as nanotheranostic platforms for targeted neurological disorder interventions (2024) · cites this paper as [146]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Staging of brain pathology related to sporadic Parkinson’s disease
Braak, H., Tredici, K. D., Rüb, U., de Vos, R. A. I., Jansen Steur, E. N. H., & Braak, E. (2003) · Neurobiology of Aging · doi:10.1016/s0197-4580(02)00065-9 · Cited by 10,777
Mutation in the α-Synuclein Gene Identified in Families with Parkinson's Disease
Polymeropoulos, M. H., Lavedan, C., Leroy, E., Ide, S. E., Dehejia, A., Dutra, A., Pike, B., Root, H., Rubenstein, J., Boyer, R., et al. (1997) · Science · doi:10.1126/science.276.5321.2045 · Cited by 8,240
MDS clinical diagnostic criteria for Parkinson’s disease
Postuma, R. B., Berg, D., Stern, M., Poewe, W., Olanow, C. W., Oertel, W., Obeso, J., Marek, K., Litvan, I., Lang, A. E., et al. (2015) · Movement Disorders · doi:10.1002/mds.26424 · Cited by 7,653
Parkinson's disease: clinical features and diagnosis
Jankovic, J. (2008) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.2007.131045 · Cited by 5,720
Overdependence on degraded gist memory in Alzheimer's disease.
Gallo, D. A., Shahid, K. R., Olson, M. A., Solomon, T. M., Schacter, D. L., & Budson, A. E. (2006) · Neuropsychology · doi:10.1037/0894-4105.20.6.625 · Cited by 4,757
Epidemiology of Parkinson's disease
de Lau, L. M., & Breteler, M. M. (2006) · The Lancet Neurology · doi:10.1016/s1474-4422(06)70471-9 · Cited by 4,110
Clinical diagnostic criteria for dementia associated with Parkinson’s disease
Emre, M., Aarsland, D., Brown, R., Burn, D. J., Duyckaerts, C., Mizuno, Y., Broe, G. A., Cummings, J., Dickson, D. W., Gauthier, S., et al. (2007) · Movement Disorders · doi:10.1002/mds.21507 · Cited by 3,027
α-Synuclein is phosphorylated in synucleinopathy lesions
Fujiwara, H., Hasegawa, M., Dohmae, N., Kawashima, A., Masliah, E., Goldberg, M. S., Shen, J., Takio, K., & Iwatsubo, T. (2002) · Nature Cell Biology · doi:10.1038/ncb748 · Cited by 2,174
Lang, A. E., & Lozano, A. M. (1998) · New England Journal of Medicine · doi:10.1056/nejm199810083391506 · Cited by 2,072
A systematic review of prevalence studies of dementia in Parkinson's disease
Aarsland, D., ZACCAI, J. H., & Brayne, C. (2005) · Movement Disorders · doi:10.1002/mds.20527 · Cited by 1,714
Flagged first, then by citations
Cited by
Sorted by citations
Items 201–300 of 312
Qin, S., Wan, X., Kong, S., Xu, K., Jin, J., He, S., & Chen, M. (2024) · Journal of Neurophysiology · doi:10.1152/jn.00351.2024 · Cited by 6
Hallbeck, M., Ekmark‐Lewén, S., Kahle, P. J., Ingelsson, M., & Reyes, J. F. (2024) · iScience · doi:10.1016/j.isci.2024.111448 · Cited by 6
Sun, L.-C., Tseng, C.-W., Lin, K.-F., & Chen, P.-N. (2025) · Digital Health · doi:10.1177/20552076251352941 · Cited by 8
Yin, S., Han, C., Xia, Y. F., Wan, F. J., Hu, J., Kou, L., Sun, Y., Wu, J., Li, Y., Zhou, Q., et al. (2022) · Molecular Neurobiology · doi:10.1007/s12035-021-02670-w · Cited by 7
Parkin characteristics and blood biomarkers of Parkinson’s disease in WPBLC study
He, H., Xiong, X., Zheng, Y., Hou, J., Jiang, T., Quan, W., Huang, J., Xu, J., Chen, K., Qian, J., et al. (2025) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2025.1511272 · Cited by 5
The Relationship Between Neuropsychiatric Disorders and the Oral Microbiome
Kalinowski, J., Ahsan, T., Ayed, M., & Esposito, M. M. (2025) · Bacteria · doi:10.3390/bacteria4030030 · Cited by 5
Meng, T., Zhang, Y., Fu, S., & Ma, S. (2025) · Research · doi:10.34133/research.0846 · Cited by 6
Cerebrospinal Fluid Biomarkers for Diagnosis of Parkinson’s disease: A Systematic Review
Dasari, M., & Medapati, R. V. (2025) · Cureus · doi:10.7759/cureus.79386 · Cited by 5
Plant poisoning leads to alpha-synucleinopathy and neuromelanopathy in kangaroos
Tayebi, M., El-Hage, C. M., Pinczowski, P., Whiteley, P., David, M. A., Li, Q., Varghese, S., Mikhael, M., Habiba, U., Harman, D. G., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-53396-8 · Cited by 6
Receptor-Dependent Endocytosis Mediates α-Synuclein Oligomer Transport Into Red Blood Cells
Li, W., Hu, J., Li, X., Lu, Z., Li, X., Wang, C., & Yu, S. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.899892 · Cited by 5
Dröden, J., & Drescher, M. (2023) · Biology · doi:10.3390/biology12010079 · Cited by 5
Yang, B., Yang, Z., Liu, H., & Qi, H. (2023) · Biosystems · doi:10.1016/j.biosystems.2023.105036 · Cited by 5
Smyth, S. P., Nixon, B., Skerrett-Byrne, D. A., Burke, N. D., & Bromfield, E. G. (2023) · Antioxidants and Redox Signaling · doi:10.1089/ars.2023.0314 · Cited by 5
Multifaceted Therapy of Nanocatalysts in Neurological Diseases
Wang, H., Chen, X., Mao, M., & Xue, X. (2021) · Journal of Biomedical Nanotechnology · doi:10.1166/jbn.2021.3063 · Cited by 5
Electrochemical Aptasensors for Parkinson’s Disease Biomarkers Detection
Mikuła, E., Katrlı́k, J., & Rodrigues, L. R. (2022) · Current Medicinal Chemistry · doi:10.2174/0929867329666220520123337 · Cited by 5
Developmental Exposure to Metals and its Contribution to Age-Related Neurodegeneration
Costa, L. G. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-804562-6.00012-9 · Cited by 5
Material-based neuroimaging and biomarker detection for central nervous system disorder
Yu, L., Zhu, Y., Zheng, X., Huang, R., Song, S., Liu, Y., Liu, Z., Chen, B., & Zhu, R. (2025) · Materials Today Bio · doi:10.1016/j.mtbio.2025.102615 · Cited by 5
Grasselli, S., Andolfi, A., Lisa, D. D., & Pastorino, L. (2025) · Frontiers in Neuroscience · doi:10.3389/fnins.2025.1584555 · Cited by 4
Liu, S., Zhu, X., Pu, H., Chen, Y., Zhu, X., Chen, L., Zhang, C., Zhang, R., & Zhong, P. (2025) · Journal of Neural Transmission · doi:10.1007/s00702-025-02940-0 · Cited by 4
Gurgone, A., Cardinale, V., Tangari, M. M., Budicin, S., Comai, D., Ledda, C., Lopiano, L., Camussi, G., Zibetti, M., & Giustetto, M. (2026) · European Journal of Neurology · doi:10.1111/ene.70508 · Cited by 4
Effect of electroacupuncture for Pisa syndrome in Parkinson’s disease: A case report
Lu, W.-J., Fan, J., Yan, M.-Y., Mukaeda, K., Zhuang, L., & Wang, L. (2022) · World Journal of Clinical Cases · doi:10.12998/wjcc.v10.i30.11023 · Cited by 4
Gao, X., Fu, J., Yu, D., Lu, F., & Liu, S. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e26916 · Cited by 4
Wan, Z., Lu, J., Lu, L., Zhao, W., & Jiang, W. (2024) · The Analyst · doi:10.1039/d4an00453a · Cited by 4
Wang, A.-Y., Hu, H., Sun, Y. P., Ou, Y., Ma, Y., Li, M., Li, Q., & Tan, L. (2024) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2024.1422772 · Cited by 4
Exploring and validating key genetic biomarkers for diagnosis of Parkinson's disease
Teng, W.-B., Deng, H.-W., Lv, B.-H., Zhou, S.-D., Li, B., & Hu, R. (2024) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2024.111165 · Cited by 4
Uchida, K., Morikawa, K., Muguruma, Y., Hosokawa, M., Tsutsumiuchi, K., Kaneda, D., Hashizume, Y., Akatsu, H., & Inoue, K. (2021) · Journal of Chromatography B · doi:10.1016/j.jchromb.2021.122885 · Cited by 4
Decreased soluble Nogo-B in serum as a promising biomarker for Parkinson's disease
Liang, H., Guo, W., He, H., Zhang, H., Ye, Q., Zhang, Q., Liao, J., Shen, Y., Wang, J., Xiao, Y., et al. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.894454 · Cited by 4
Juárez-Vaquera, V. H., Sciutto, M. F. R., Morales-Ruiz, V., & Adalid-Peralta, L. V. (2023) · Revista de investigaci�n Cl�nica · doi:10.24875/ric.23000017 · Cited by 4
Wang, T., Liu, W., Zhang, Q., Jiao, J., Wang, Z., Gao, G., & Yang, H. (2024) · Cells · doi:10.3390/cells13090739 · Cited by 4
Diagnostic validity of biomarkers in Parkinson’s Disease: systematic review and meta-analysis
da Costa, M. F. B. N. A., Reisdorfer, E., Kempfer, S. S., Manfrini, G. C., Porporatti, A. L., & Canto, G. D. L. (2018) · Revista Brasileira de Enfermagem · doi:10.1590/0034-7167-2017-0822 · Cited by 4
Stevens, K. G., McFarlane, L. O., Platts, K., O’brien-simpson, N. M., Li, W., Blencowe, A., Trim, P. J., & Pukala, T. L. (2021) · Analytical Chemistry · doi:10.1021/acs.analchem.1c00193 · Cited by 4
Decreased serum levels of α‐synuclein in patients with schizophrenia and their unaffected siblings
Göverti, D., Büyüklüoğlu, N., Yüksel, R. N., Kaya, H., Yücel, Ç., & Göka, E. (2023) · Early Intervention in Psychiatry · doi:10.1111/eip.13398 · Cited by 4
Naciri, L. C., Melis, M., Sollai, G., Deligia, S., Fenu, G., Mellino, P., Pinna, B., Crnjar, R., Cossu, G., & Barbarossa, I. T. (2025) · Neurobiology of Disease · doi:10.1016/j.nbd.2025.107172 · Cited by 3
Wang, X., Qi, L.-L., Wang, J.-M., Sun, Y.-R., Lv, Q.-K., Cao, B., Jiang, S., Ma, Q., Liu, C., Liu, J., et al. (2025) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-025-05995-0 · Cited by 3
Microfluidic platform for understanding Parkinson’s disease and α-synuclein conformation
Tregub, P. P., Zembatov, G. M., Namiot, E., Natalia, K., Stanislav, Y., Sergey, I., & Salmina, A. B. (2025) · Translational Neurodegeneration · doi:10.1186/s40035-025-00526-0 · Cited by 3
Zhang, Q., Lin, Z., He, Y., Jiang, J., & Hu, D. (2023) · Molecular Neurobiology · doi:10.1007/s12035-023-03206-0 · Cited by 3
Bioanalytical Considerations for Biomarkers of Parkinson's Disease
Huang, A., Foti, R., Gunawardana, C. G., Shen, H., & Xiao, Y. (2025) · Journal of Neurochemistry · doi:10.1111/jnc.70131 · Cited by 4
Application of serum peptidomics for Parkinson's disease in SNCA-A30P mice
Yin, Z., Xu, G., Qi, Y., Tan, D.-M., Chen, E.-H., Xu, D., & Ji, R.-Y. (2023) · Heliyon · doi:10.1016/j.heliyon.2023.e21125 · Cited by 3
Non-motor symptoms in prodromal Parkinson's disease are linked to reduced quality of life
Röttgen, S., Lindner, M., Seger, A., Kickartz, J., Weiß, K.-L., Doppler, C. E. J., Fink, G. R., Ophey, A., & Sommerauer, M. (2025) · Journal of Parkinson s Disease · doi:10.1177/1877718x241310726 · Cited by 3
Kukreja, V., Ahuja, V., Ati, M., Hariharan, S., Krishnamoorthy, M., Sharma, R., & Bhattacherjee, A. (2025) · Results in Engineering · doi:10.1016/j.rineng.2025.105317 · Cited by 3
Development of a hydroxyflavone-labelled 4554W peptide probe for monitoring αS aggregation
Watt, K. J. C., Meade, R. M., James, T. D., & Mason, J. M. (2023) · Scientific Reports · doi:10.1038/s41598-023-37655-3 · Cited by 3
Neurodegenerative Diseases as Protein Folding Disorders
Baker, J. D., Webster, J. M., Shelton, L. B., Koren, J., Uversky, V. N., Blair, L. J., & Dickey, C. A. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-811304-2.00009-2 · Cited by 3
Stuckey, S. M., Hood, R. J., Ong, L. K., Bilecki, I. M., Collins‐Praino, L. E., & Turner, R. J. (2025) · Neuroprotection/Neuroprotection (Chichester, England. Print) · doi:10.1002/nep3.74 · Cited by 2
Liu, J., Wang, S., Fan, L., Zhou, X., Zhang, S., Wang, Q., Dong, P., & Yu, B. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1615001 · Cited by 2
Aghakhani, N., Arzoo, A., Dorflinger, B. G., Athari, S. Z., & Mohaddes, G. (2025) · Brain Disorders · doi:10.1016/j.dscb.2025.100297 · Cited by 2
Gündoğdu, Ö. L., Burul, F., Akyol, E. T., Okkay, U., Yeşilyurt, F., Yildiz, F. B., Okkay, I. F., Özkaraca, M., & Hacımüftüoğlu, A. (2026) · Scientific Reports · doi:10.1038/s41598-026-40095-4 · Cited by 2
Bala, K., & Aran, K. R. (2024) · Aging and Health Research · doi:10.1016/j.ahr.2024.100206 · Cited by 2
Avagyan, S., Muradyan, A., Makletsova, M. G., Полещук, В. В., & Zilfyan, A. (2025) · THE NEW ARMENIAN MEDICAL JOURNAL · doi:10.56936/18290825-3.19v.2025-4 · Cited by 2
Metabolomic Biomarkers in Parkinson’s Disease
Shao, Y., Xu, X., Wang, N., Xu, G., & Le, W. (2021) · Neuromethods · doi:10.1007/978-1-0716-1712-0_8 · Cited by 2
Shalash, A., Doma, A., Barakat, M., Hamid, E., & Salama, M. (2024) · Biomedical Reports · doi:10.3892/br.2024.1796 · Cited by 1
Advances in Aggrephagy: Mechanisms, Disease Implications, and Therapeutic Strategies
Zhuang, H., & Ma, X. (2025) · Journal of Cellular Physiology · doi:10.1002/jcp.31512 · Cited by 3
The Microbial and Metabolic Link Between Gut and Brain
Salamalek, R., Shareef, Y., Abdulridha, F., & Soliman, S. S. M. (2025) · Springer eBooks · doi:10.1007/978-981-96-1305-2_17 · Cited by 1
Nielsen, S. H., Hausgaard, C. M., Benmarce, M., Karsdal, M. A., & Henriksen, K. (2025) · Scientific Reports · doi:10.1038/s41598-025-92726-x · Cited by 1
Vedadi, Z., Miandehi, E. E., Akbari, M., Shoeibi, A., Vedadi, D., Eslami, S., & Taherzadeh, Z. (2026) · Scientific Reports · doi:10.1038/s41598-026-36736-3 · Cited by 1
Selective neurodegeneration in patients with parkinson’s disease
Yusupov, F. A., & Abdykadyrov, M. S. (2026) · S S Korsakov Journal of Neurology and Psychiatry · doi:10.17116/jnevro202612602123 · Cited by 1
Extracellular vesicles – upcoming biomarkers in Parkinson's disease's biofluids
Weiß, A., Matamoros‐Angles, A., Boros, F. A., Arnold, P., & Zunke, F. (2022) · Trillium Extracellular Vesicles · doi:10.47184/tev.2022.01.06 · Cited by 1
Wang, Q.-R., Yu, X. F., Li, Y., & Ming-zhen, Z. (2024) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2024.110959 · Cited by 1
AIMP2 accumulation in brain leads to cognitive deficits and blood secretion in Parkinson’s disease
Kim, H., Shin, J., Ham, S., Kim, J. H., Lee, G. H., Lee, N., Kim, H.-T., Cho, S. H., Kim, S. S., & Lee, Y. (2024) · Journal of Translational Medicine · doi:10.1186/s12967-024-05666-x · Cited by 1
Chen, Y., Gu, Y., Cao, C., Zheng, Q., Sun, L., Ding, W., Ma, L., Wang, C., & Zhang, W. (2024) · Neurochemical Research · doi:10.1007/s11064-024-04250-5 · Cited by 1
Heikal, S. A., Fawi, G., Moustafa, S. A., Barakat, M., Ragab, G., Hegazy, M. T., ElFarash, S., & Salama, M. (2024) · Alzheimer s & Dementia · doi:10.1002/alz.093274 · Cited by 1
Using Human Neural Stem Cells as a Model to Understand the “Science of Ashwagandha”
Tewari, M., Pandey, H. S., & Seth, P. (2017) · Springer eBooks · doi:10.1007/978-3-319-59192-6_16 · Cited by 1
Verma, M., Basu, S., Singh, M., Rachana, R., Kaur, S., & Goel, N. (2020) · Advances in medical diagnosis, treatment, and care (AMDTC) book series · doi:10.4018/978-1-7998-1317-0.ch008 · Cited by 1
Dhokne, S. V., Undale, V., Agrawal, D. C., & Pawar, S. D. (2021) · Springer eBooks · doi:10.1007/978-981-33-4141-8_9 · Cited by 1
Moreno, A. J., Luthra, N., Bonham, L. W., Lin, J. Y., Broestl, L., Bétourné, A., Sehgal, R., Wang, D., Lesné, S., Ostrem, J. L., et al. (2020) · Research Square · doi:10.21203/rs.3.rs-89525/v1 · Cited by 1
A blood marker for Parkinson’s Disease: Neuronal exosome-derived α-synucleinPreprint
Kluge, A., Bunk, J., Schaeffer, E., Drobny, A., Xiang, W., Knacke, H., Bub, S., Lückstädt, W., Arnold, P., Lucius, R., et al. (2021) · Research Square · doi:10.21203/rs.3.rs-783910/v1 · Cited by 1
α‐Synuclein in Neurodegeneration—A Good Protein that may go Bad
Zetterberg, H., & Brinkmalm, A. (2016) · Brain Pathology · doi:10.1111/bpa.12372
Melo, T. Q. (2017) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.5.2017.tde-01032017-131637
Altered hypothalamic diffusivity in Parkinsonian autonomic dysfunctionPreprint
Rousseau, C., Sklerov, M., Browner, N., Lee, Y. Z., Boucaud, A., Prieto, J. C., Styner, M. A., & Dayan, E. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/767624
Biriuk, V. V., Демченко, А. В., & Горбачова, С. В. (2020) · Biological Markers and Guided Therapy · doi:10.12988/bmgt.2020.91020
The contribution of gut microbiota in the pathogenesis of Parkinson’s disease
Farooqui, T. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-821039-0.00008-3
Perspectives of Aptamers for Medical Applications
Jin, H. (2021) · Springer eBooks · doi:10.1007/978-981-33-4838-7_14
Westgotenzeitiche Kapitelle im Duero-Gebiet und in Asturiem: "mit 2 Textabbiidungen und Tafel 78-82"
Noack-Haley, S. (1986) · Madrider Mitteilungen
ROLE OF BIOMARKERS IN EPILEPTOGENESIS: A CONCISE REVIEW
Baravkar, A. A., SHINDE, S. D., & Aher, N. B. (2022) · International Journal of Pharmacy and Pharmaceutical Sciences · doi:10.22159/ijpps.2022v14i1.43306
Novel Theranostics for Parkinson's Disease
Schlichtmann, B. W. (2021) · doi:10.31274/td-20240329-549
Liu, Z., Huang, Y. X. R., Wang, X., Li, J., Zhang, C., Yang, Y., & Zhang, J. (2023) · Figshare · doi:10.6084/m9.figshare.22625693
Self-citationTarianyk, K. А. (2024) · The Medical and Ecological Problems · doi:10.31718/mep.2024.28.2.05
Biomarkers in Parkinson’s Disease
Deng, H., Li, T., Liu, X., Shao, Y., Yang, Z., Li, S., & Le, W. (2025) · Cambridge University Press eBooks · doi:10.1017/9781108989855.021
Futuristic therapeutics in pipeline for the betterment of neurodegenerative disorders
Upadhyay, H., Das, P., Sanskriti, Biswal, S., & Das, D. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-29932-2.00014-1
Hallbeck, M., Ntzouni, M. P., Ingelsson, M., & Reyes, J. F. (2025) · STAR Protocols · doi:10.1016/j.xpro.2025.104158
Nano-Bioelectronics for Neurodegenerative Disease Monitoring and Management
Panicker, L. R., Bukya, K., Kotagiri, N., & Goud, Y. K. (2025) · Springer eBooks · doi:10.1007/978-981-95-2117-3_9
Ichie, K. E., Asomugha, L. A., & Okafor, I. A. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.11.20.689379
Reyes, J. F., Ekmark‐Lewén, S., Perdiki, Μ., Klingstedt, T., Hoffmann, A., Wiecheć, E., Nilsson, P., Nilsson, K. P. R., Alafuzoff, I., Ingelsson, M., et al. (2021) · Figshare · doi:10.6084/m9.figshare.14253576
Ibanez, L., Bahena, J. A., Yang, C., Dube, U., Farias, F. G., Budde, J. P., Bergmann, K., Brenner-Webster, C., Morris, J. C., Perrin, R. J., et al. (2020) · Figshare · doi:10.6084/m9.figshare.13265837
Reyes, J. F., Ekmark‐Lewén, S., Perdiki, Μ., Klingstedt, T., Hoffmann, A., Wiecheć, E., Nilsson, P., Nilsson, K. P. R., Alafuzoff, I., Ingelsson, M., et al. (2021) · Figshare · doi:10.6084/m9.figshare.14253567
Reyes, J. F., Ekmark‐Lewén, S., Perdiki, Μ., Klingstedt, T., Hoffmann, A., Wiecheć, E., Nilsson, P., Nilsson, K. P. R., Alafuzoff, I. I., Ingelsson, M., et al. (2021) · Figshare · doi:10.6084/m9.figshare.14253573
Reyes, J. F., Ekmark‐Lewén, S., Perdiki, Μ., Klingstedt, T., Hoffmann, A., Wiecheć, E., Nilsson, P., Nilsson, K. P. R., Alafuzoff, I., Ingelsson, M., et al. (2021) · Figshare · doi:10.6084/m9.figshare.14253570
Liu, Z., Huang, Y. Z., Wang, X., Li, J., Zhang, C., Yang, Y., & Zhang, J. (2023) · Figshare · doi:10.6084/m9.figshare.22625690
Self-citationEpigenetics in neurodegeneration: Emerging biomarkers and translational insights
Singh, H., Gurjar, S., & Taliyan, R. (2025) · Brain Research · doi:10.1016/j.brainres.2025.150005
Applying the Estimand Framework: Case Studies in Neuroscience
Burger, H. U., Sfikas, N., Magnusson, B., Josiassen, M. K., Quarg, P., Monnet, A., Anzures‐Cabrera, J., Shariati, N., & Delmar, P. (2025) · Springer series in pharmaceutical statistics · doi:10.1007/978-3-032-02192-2_9
Priya, Mittal, R., Banerjee, J., & Dixit, A. B. (2026) · International review of neurobiology · doi:10.1016/bs.irn.2026.02.006
Dong, Z., Dai, F., Xing, N., Wu, Q., Gao, H., Kan, P., Han, Y., Cheng, X., Wang, Y., Feng, X., et al. (2026) · Clinical Neurology and Neurosurgery · doi:10.1016/j.clineuro.2026.109425
Velmurugan, G., Upadhyay, R., Sevanan, M., Francis, D., Bougea, A. M., & Chinnathambi, S. (2026) · Advances in pharmacology · doi:10.1016/bs.apha.2026.01.001
Hu, J., Zang, H., Li, H., Yang, W., Luo, J., Tan, Y., Zhuan, L., & Liu, N. (2026) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2026.117825
Nayak, M., Singh, A. K., & Singh, R. K. (2026) · Microchimica Acta · doi:10.1007/s00604-026-08042-2
Future perspectives: Toward universal early detection of chronic diseases
Hooshmandi, E. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-33263-0.00005-x
Alobaed, A. (2026) · Research Square · doi:10.21203/rs.3.rs-9238596/v1
Melis, M., Angius, F., Naciri, L. C., Sollai, G., Deligia, S., Fenu, G., Mellino, P., Pinna, B., Crnjar, R., Carta, A. R., et al. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27094048
Photonic and nanomaterial-driven optical biosensing strategies for Parkinson’s disease
Soni, D., & Ratre, P. (2026) · Microchimica Acta · doi:10.1007/s00604-026-08068-6
Stem Cell Therapy for Parkinson’s Disease: A Mechanistically Distinct Role for Muse Cells
Mesches, M. H., Granholm, A., Paredes, D., Coleman-Mesches, K., Oguma, Y., & Dezawa, M. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15114370
Metadata
- Authors
- Atik, A., Stewart, T., & Zhang, J.
- Affiliations
- University of Washington (US)
- ORCID
- Zhang, Jing
- Venue
- Brain Pathology
- Publisher
- Wiley
- Published
- 2016-04-25
- Volume
- 26
- Issue
- 3
- Pages
- 410-418
- ISSN
- 1015-6305 (ISSN-L)
- 1750-3639
- PMC
- PMC6245641
- OpenAlex
- W2289901196
- Cited by
- 311
- References
- 119
- Citations by year
- 2026: 25 · 2025: 42 · 2024: 36 · 2023: 42 · 2022: 36 · 2021: 42 · 2020: 40 · 2019: 15 · 2018: 13 · 2017: 12 · 2016: 7
- FWCI
- 2.17
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Brain Pathology (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (NIH) (U01 NS082137, P30 ES007033-6364, R01 AG033398, R01 ES016873, R01 ES019277, R01 NS057567, and P50 NS062684-6221)
- Topics
- Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Clinical Neurology › Deep Brain Stimulation and Movement Disorders
- Keywords
- alpha-synuclein, Parkinson's disease, biomarkers, Lewy bodies, early diagnosis, disease progression monitoring, cerebrospinal fluid, plasma, blood, saliva, combined biomarkers, neurodegeneration
- MeSH terms
- Humans, Parkinson Disease, Biomarkers, alpha-Synuclein
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
